Minerva Neurosciencs to request meeting with FDA about schizophrenia drug

Minerva Neurosciences Inc. NERV, -65.90% said Monday that it received a refusal to file letter from the Food and Drug Administration for its application for roluperidone as a treatment for patients with schizophrenia. “The company intends to request a Type A meeting and looks forward to continued discussions with the FDA,” Minerva CEO said in a news release. Minerva’s stock has soared 109.6% so far this year, while the broader S&P 500 SPX, +2.66% has declined 24.8%.